Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment-Reference-Cited by-同舟云学术

Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment

Published:2020-11 Issue: Volume:418 Page:117102
ISSN:0022-510X
Container-title:Journal of the Neurological Sciences
language:en
Short-container-title:Journal of the Neurological Sciences

Author:

Das Arabinda,Alshareef Mohammed,Porto Guilherme Bastos Ferreira,Infinger Libby Kosnik,Vandergrift William A.,Lindhorst Scott M.,Varma Abhay K.,Patel Sunil J.,Cachia David

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology

Reference33 articles.

1. Malignant Gliomas;Burton;Curr. Treat. Options in Oncol.,2000

2. Glioblastoma mMultiforme, diagnosis and treatment; recent literature review;Batash;Curr. Med. Chem.,2017

3. Potential strategies overcoming the Temozolomide resistance for Glioblastoma;Jiapaer;Neurol. Med. Chir. (Tokyo),2018

4. Novel MSH6 mutations in treatment-Naïve Glioblastoma and anaplastic Oligodendroglioma contribute to Temozolomide resistance independently of MGMT promoter methylation;Nguyen;Clin. Cancer Res.,2014

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation;Pharmaceuticals;2024-02-02

2. Endosome associated trafficking regulator 1 promotes tumor growth and invasion of glioblastoma multiforme via inhibiting TNF signaling pathway;Journal of Neuro-Oncology;2024-01

3. Endosome associated trafficking regulator 1 promotes tumor growth and invasion of glioblastoma multiforme via inhibiting TNF signaling pathway;2023-11-21

4. An End-to-end In-Silico and In-Vitro Drug Repurposing Pipeline for Glioblastoma;2023 IEEE 11th International Conference on Healthcare Informatics (ICHI);2023-06-26

5. YTHDF2 promotes temozolomide resistance in glioblastoma by activation of the Akt and NF‐κB signalling pathways via inhibiting EPHB3 and TNFAIP3;Clinical & Translational Immunology;2022-01